Treatment of attention-deficit/hyperactivity disorder

• US 5,658,590 A
• Filed: 01/11/1995
• Issued: 08/19/1997
• Est. Priority Date: 01/11/1995
• Status: Expired due to Term

• Current Assignee: Eli Lilly and Company
• Original Assignee: Eli Lilly and Company
• Inventors: Heiligenstein, John H., Tollefson, Gary D.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): Spear, James M.
• Application Number:
  US08/371,341
• Time in Patent Office: 951 Days
• Field of Search: 424/464, 424/451, 424/489, 514/646, 514/651
• US Class Current: 424/464
• CPC Class Codes: A61K 31/138 Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Tomoxetine, a norepinephrine uptake inhibitor, is used to treat attention-deficit/hyperactivity disorder.

Claims

1. A method of treating attention-deficit/hyperactivity disorder comprising administering to a patient in need of such treatment an effective amount of tomoxetine.

2. A method of claim 1 wherein the predominantly inattentive type of attention-deficit/hyperactivity disorder is treated.

3. A method of claim 1 wherein the predominantly hyperactive-impulsive type of attention-deficit/hyperactive disorder is treated.

4. A method of claim 1 wherein the combined type of attention-deficit/hyperactivity disorder is treated.

5. A method of claim 1 wherein the patient is an adult.

6. A method of claim 5 wherein the predominantly inattentive type of attention-deficit/hyperactivity disorder is treated.

7. A method of claim 5 wherein the predominantly hyperactive-impulsive type of attention-deficit/hyperactive disorder is treated.

8. A method of claim 5 wherein the combined type of attention-deficit/hyperactivity disorder is treated.

9. A method of claim 1 wherein the patient is an adolescent.

10. A method of claim 9 wherein the predominantly inattentive type of attention-deficit/hyperactivity disorder is treated.

11. A method of claim 9 wherein the predominantly hyperactive-impulsive type of attention-deficit/hyperactive disorder is treated.

12. A method of claim 9, wherein the combined type of attention-deficit/hyperactivity disorder is treated.

13. A method of claim 1 wherein the patient is a child.

14. A method of claim 13 wherein the predominantly inattentive type of attention-deficit/hyperactivity disorder is treated.

15. A method of claim 13 wherein the predominantly hyperactive-impulsive type of attention-deficit/hyperactive disorder is treated.

16. A method of claim 13 wherein the combined type of attention-deficit/hyperactivity disorder is treated.